The etiology of MAS after TCZ administration remains unclear; however, it may be because TCZ is an IL-6 receptor antibody, rather than a drug that directly neutralizes IL-6, and serum IL-6 levels temporarily increase after TCZ administration [24]. Here, IL6 is linked to macrophage activation syndrome.